Targeting WNT/β-Catenin via Modulating EZH2 Function: A New Chapter in the Treatment of β-Catenin Mutant Hepatocellular Carcinoma?

被引：1

作者：

Hung, Man Hsin ^{[1
]}

Wang, Xin Wei ^{[1
,2
,3
,4
]}

机构：

[1] NCI, Ctr Canc Res, Lab Human Carcinogenesis, Bethesda, MD USA

[2] NCI, Ctr Canc Res, Liver Canc Program, Bethesda, MD USA

[3] NCI, Lab Human Carcinogenesis, Bethesda, MD 20892 USA

[4] NCI, Liver Canc Program, Bethesda, MD 20892 USA

来源：

CANCER RESEARCH | 2023年 / 83卷 / 21期

关键词：

MICE;

D O I：

10.1158/0008-5472.CAN-23-2921

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a recent study, Rialdi and colleagues identified a specific vulnerability in beta-catenin mutant hepatocellular carcinoma (HCC) via EZH2-mediated suppression of WNT signaling and revealed the selective anti-HCC activity of WNTinib, a chemical derivative of regorafenib and sorafenib in targeting this vulnerability. Their discoveries highlight the role of EZH2 in modulating WNT signaling and suggest an implication of WNTinihb as a small-molecule inhibitor for the treatment of HCC with activated WNT/beta-catenin.

引用

页码：3498 / 3500

页数：3